lenvatinib

Overview

Lenvatinib is an orally administered multi-targeted tyrosine kinase inhibitor. It blocks the vascular endothelial growth factor receptors VEGFR1–3, which carries most of its antiangiogenic effect, together with the fibroblast growth factor receptors FGFR1–4, PDGFRα, KIT and RET. The FGFR component distinguishes it from earlier antiangiogenics such as sorafenib: FGF signaling is a common escape route when VEGF alone is blocked, and inhibiting both at once is the rationale for its broader activity. Structurally it binds the ATP site in a distinctive way that gives rapid, tight association, and it is dosed by body weight rather than uniformly.

Its approvals span radioiodine-refractory differentiated thyroid cancer, where it produces high response rates; unresectable hepatocellular carcinoma as first-line therapy after showing non-inferior survival against sorafenib; advanced renal cell carcinoma with everolimus or with pembrolizumab; and advanced endometrial carcinoma with pembrolizumab in mismatch repair–proficient disease. It is also studied as a comparator or backbone in liver cancer more broadly, thyroid cancer, lung adenocarcinoma and biliary tract malignancies.

Combination with immune checkpoint blockade is the dominant current direction, on the rationale that reducing VEGF-driven immunosuppression makes tumors more susceptible to T-cell attack: partners include anti-PD-1/PD-L1 antibodies such as pembrolizumab, sintilimab, durvalumab and nivolumab, the PD-1/CTLA-4 bispecific cadonilimab, and locoregional approaches — hepatic arterial infusion chemotherapy, stereotactic body radiotherapy and surgery — with conversion of unresectable disease to resectable an explicit goal. The toxicities are those of potent VEGFR blockade and limit delivery of the intended dose: hypertension in most patients, proteinuria, fatigue, diarrhea, hand-foot skin reaction, hypothyroidism and impaired wound healing, with dose reduction common.

Recent Publications Summary

Recent publications on lenvatinib focused largely on its use as part of combination regimens in hepatocellular carcinoma and other solid tumors, as well as on mechanisms of resistance and delivery optimization. In unresectable hepatocellular carcinoma, lenvatinib was studied with nivolumab in a single-arm phase 2 trial, where 49 treated patients had an objective response rate of 32%, median progression-free survival of 9.0 months, and median overall survival of 26.6 months 42284972Jun. Lenvatinib also appeared in multiple conversion-therapy strategies, including sintilimab plus lenvatinib followed by sequential surgery, which achieved successful conversion in 56% of 120 patients and reported objective response rates of 58.3% by mRECIST and 45.8% by RECIST v1.1, with a median overall survival of 36.0 months 42091859May. Another phase 2 study evaluated hepatic arterial infusion chemotherapy with FOLFOX, lenvatinib, and durvalumab in unresectable hepatocellular carcinoma, reporting a median progression-free survival of 15.8 months and an objective response rate of 75.0% 42135293May. A study protocol also proposed cadonilimab plus lenvatinib with stereotactic body radiotherapy as conversion therapy for potentially resectable or unresectable hepatocellular carcinoma 41954707Apr.

Several studies examined lenvatinib in combination with immune checkpoint blockade across tumor types. In recurrent/metastatic head and neck squamous cell carcinoma, the randomized phase 2 LEAP-009 trial compared lenvatinib plus pembrolizumab with standard of care or lenvatinib monotherapy, with the primary focus on overall survival and secondary safety endpoints 42241967Jun. In advanced renal cell carcinoma, Bayesian analysis was used to refine East Asian subgroup estimates for lenvatinib plus pembrolizumab in the CLEAR trial and to assess safety while preserving region-specific toxicity 42373289Jun. Real-world and comparative studies also evaluated pembrolizumab plus lenvatinib in metastatic renal cell carcinoma and anaplastic thyroid carcinoma, reflecting continued interest in this regimen outside hepatocellular carcinoma 42204034May41973603Apr. In hepatocellular carcinoma, a real-world pharmacovigilance analysis identified adverse-event signals associated with pembrolizumab plus lenvatinib, including immune-mediated hepatitis, hepatic encephalopathy, and upper gastrointestinal haemorrhage 42461453Jul.

Other publications addressed lenvatinib as a second-line option and as a platform for mechanistic or translational research. In a multicenter prospective cohort of advanced hepatocellular carcinoma after atezolizumab plus bevacizumab, second-line lenvatinib was associated with longer median progression-free survival than sorafenib and regorafenib, although overall survival did not differ significantly 41944032Apr. A separate comparison of second-line durvalumab plus tremelimumab versus lenvatinib after first-line atezolizumab plus bevacizumab was also reported in unresectable hepatocellular carcinoma 42096473May. Mechanistic studies described multiple resistance pathways, including RPRD1A-driven lenvatinib resistance via the ITGA5-FAK axis 42171939May, an EGR1-ZNF768-SLC7A11 adaptive response limiting ferroptosis-mediated efficacy 42116728May, lactylation of ABHD6 promoting mitochondrial adaptation and resistance 41861279Mar, and DEHP-induced epithelial-mesenchymal transition reducing lenvatinib responsiveness through SPAG4-dependent MAPK/ERK signaling 42126986May. Additional work explored topical ocular delivery of lenvatinib for choroidal neovascularization using cR10-modified liposomes, which enhanced cellular uptake and suppressed neovascular lesion formation and vascular leakage in an animal model 42225176Jun, and a biomimetic Mn-doped polydopamine nanoplatform designed to improve lenvatinib accumulation and support MRI-enabled synergistic therapy in liver cancer 42003816Apr.

What Changes, What Holds

1. Lenvatinib is moving from a backbone drug to a conversion-therapy component with potentially curative intent in selected unresectable HCC
NEW DIRECTION The new work does not displace its established role in advanced hepatocellular carcinoma, but it does extend that role toward sequential surgery and multimodality conversion strategies, where lenvatinib is being used to help render initially unresectable disease operable. The phase 2 and protocol-level evidence is still early, yet it suggests the drug’s value may increasingly be judged by resectability and durable disease control rather than response alone 42284972Jun42091859May.

2. Lenvatinib is being tested as a broader immunotherapy partner, but the main message is still confirmation rather than reversal
REINFORCES These studies strengthen the view of lenvatinib as a combination backbone across solid tumors, especially where checkpoint blockade is central, and they also show that its use is expanding beyond HCC into head and neck, renal, and thyroid Cancers. The pharmacovigilance signal for immune-mediated and bleeding toxicities adds practical caution, but it does not contradict the baseline’s combination-centric role; it mainly sharpens expectations about safety monitoring 42241967Jun42461453Jul.

3. Lenvatinib remains a viable later-line option after atezolizumab-bevacizumab, but its advantage may be limited to disease control rather than survival
NEW DIRECTION The prospective cohort data support lenvatinib as a preferred second-line choice over some alternatives after first-line atezolizumab plus bevacizumab, yet the lack of a clear overall-survival difference keeps the clinical meaning incomplete. That places the drug in a more nuanced post–immunotherapy sequence than the baseline describes: useful for progression control, but not yet proven to change the ultimate trajectory. The comparative durvalumab-tremelimumab report and the resistance studies further suggest that sequencing remains unsettled 41944032Apr42096473May.

Overview update candidates: conversion-therapy use in unresectable HCC; broader checkpoint-inhibitor combinations and toxicity signals; second-line positioning after atezolizumab-bevacizumab; resistance mechanisms.